Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. 3-Phenyllactic Acid has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Lactic acid bacteria and bifidobacteria transaminate phenylalanine to phenylpyruvate, then reduce it to 3-phenyllactic acid. Substrate availability is the main limit on how much of the acid a culture makes, which is why fermentation media are often phenylalanine-supplemented. In the gut, dietary and endogenous phenylalanine reaching the colon is the source. The pathway runs in the bacteria, not in human tissue.
Bifidobacterium longum subsp. infantis is one of the better characterised producers of aromatic lactic acids including the phenyl form, and its output is tied to how it handles aromatic amino acids. This makes the compound a marker of a particular microbial activity rather than something usually swallowed on its own. Pairing the organism with substrate is the practical route to raising it.
Lactobacillus plantarum produces 3-phenyllactic acid during fermentation, and much of the antifungal activity attributed to its culture supernatants tracks with this and related acids. It is one reason fermented foods carry the compound. The activity is documented in food and culture systems rather than in people.
Across mixed cultures, aromatic lactic acid output depends on which species are present and on aromatic amino acid supply. A general probiotic blend may raise or may not raise this specific metabolite, since the capacity is strain-dependent. Anyone targeting it should look at strain-level data rather than assume it from a genus name.
Adding a fermentable fibre changes which organisms dominate colonic fermentation and how much protein and amino acid fermentation happens. That can shift aromatic metabolite output in either direction. The link to this specific compound is inferred from pathway logic, and it has not been measured directly in humans.
Protein intake determines how much phenylalanine is available, including the fraction that escapes small intestinal absorption and reaches colonic bacteria. More undigested protein reaching the colon means more aromatic amino acid fermentation. This is a plausible upstream lever, not a demonstrated way to move the metabolite in people.
Nothing specific on file for 3-Phenyllactic Acid. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 3 we read for 3-Phenyllactic Acid. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.